Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: "and Death Shall Have no Dominion"?

Curr Vasc Pharmacol. 2016;14(4):316-8. doi: 10.2174/1570161114999160229142200.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Benzhydryl Compounds / therapeutic use*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / mortality
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / mortality*
  • Glucosides / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use*

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Hypoglycemic Agents
  • empagliflozin